Interpretational.com – Page 2 – Interpretational.com is an available dictionary domain

Seagen and Astellas Announce Positive Topline Results from Second Cohort of Patients in Phase 2 Pivotal Trial of PADCEV® (enfortumab vedotin-ejfv) in Advanced Urothelial Cancer

BOTHELL, Wash. & TOKYO–(BUSINESS WIRE)–Oct 12, 2020– Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced positive topline results from the second cohort of patients in the pivotal phase 2 single-arm clinical trial known as EV-201. The cohort is evaluating the antibody-drug conjugate PADCEV ® (enfortumab vedotin-ejfv) for patients with locally...

Seattle Genetics and Astellas Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer

BOTHELL, Wash. & TOKYO–(BUSINESS WIRE[1])–Seattle Genetics, Inc[2]. (Nasdaq:SGEN) and Astellas Pharma Inc.[3] (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that a phase 3 trial of PADCEV® (enfortumab vedotin-ejfv) met its primary endpoint of overall survival compared to chemotherapy. The results were reviewed by an independent Data Monitoring Committee following a planned interim analysis. The global EV-301...

Justice Thomas Repudiates Brand X Decision He Authored, but High Court Denies Cert

WASHINGTON, D.C., Feb. 24, 2020 (GLOBE NEWSWIRE) — Howard and Karen Baldwin got their day in court—and won—but then the Brand X doctrine took it all away. The New Civil Liberties Alliance commends Supreme Court Justice Clarence Thomas for dissenting from the Court’s denial of a writ of certiorari this morning sought by NCLA’s clients in their case against the...

Ligand Presents Positive Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol

SAN DIEGO–(BUSINESS WIRE[1])–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) presented positive results today from a Phase 1 clinical trial of its Captisol-enabled (CE) Iohexol program at ASN Kidney Week 2019 in Washington, D.C. The CE-Iohexol program was established in January 2018 to develop a Captisol-enabled, next-generation contrast agent for diagnostic imaging with a reduced risk of renal toxicity. The trial achieved the...